Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Small Cell Lung Cancer: early-phase trial registry
1 of 6 indexed Recurrent Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Recurrent Small Cell Lung Cancer: 6 US clinical trials tracked, 1 recruiting.
Recurrent Small Cell Lung Cancer is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-small-cell-lung-cancer
OPEN 1 | RECR 17% | LATE 0 | EARLY 6 | RANK #2866 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Recurrent Small Cell Lung Cancer lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Small Cell Lung Cancer is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Small Cell Lung Cancer research.
National Cancer Institute (NCI) accounts for 4 of 6 trials (66.7%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Small Cell Lung Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 36 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Recurrent Small Cell Lung Cancer research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
VA Office of Research and Development
NCT06681220
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00470054
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00086827
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
NCT00028535
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00773955
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Wake Forest University Health Sciences
NCT01931787
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Small Cell Lung Cancer page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Small Cell Lung Cancer condition card totals 6 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.